Corresponding with lower ferroportin levels were higher observed levels of hepcidin in AD patient serum compared to controls (Sternberg et al., 2017), although the study did not test for a correlation with cognitive decline. This evidence concerns the gene SLC40A1 and Alzheimer disease.